Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Q4 2024 Earnings Call Transcript February 28, 2025 Gem Hopkins: Good morning and good afternoon, everyone. Thank you for ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an ...

She says, the PV aspect means that you have to have phlebotomies regularly. And I think the most crippling thing about that is the fatigue. We are hopeful based on the SANRECO Phase 1 data that ...

Silence Therapeutics PLC (SLN) experienced a notable premarket stock price increase of 5.24%, following its earnings call for the fiscal year 2024. The company’s strategic collaborations and ...